How to use the speech recognition tool?

CURETINA

CURETINA

CURETINA personalized medicine in hereditary retinal degenerations

Type: Observational



Status of the trial: Completed

Orphan Drug Recognition: NA

Inclusion

  • Opening Date: 0000-00-00
  • Closing Date: 2018-06-30

Criteria

Inclusion: Retinal degeneration caused by mutations in either of the genes CRB1, CRX, PROM1

Exclusion: Additional mutations in genes known for causing hereditary retinal degenerations; additional eye diseases influencing the retinal morphology and function (glaucoma, retinal detachment, etc.)

Children: Yes

Adults: Yes

Funder Type: national institution

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: